FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385661567> ?p ?o ?g. }

• W4385661567 abstract "PRESTO 3 evaluated nurses' preference for the Somatuline® Autogel® syringe versus the Lanreotide Pharmathen syringe after injection-pad testing.This international simulated-use study included oncology/endocrinology nurses with ≥ 1 years' experience in managing neuroendocrine tumours (NETs) and/or acromegaly. Each nurse tested both syringes twice in a randomised order before completing an electronic survey. The primary objective was to assess overall preference (%, 95% confidence interval [CI]) for the Somatuline Autogel syringe versus the Lanreotide Pharmathen syringe. Secondary objectives included rating syringe performance and ranking the importance of syringe attributes.Ninety-four nurses were enrolled: mean age, 41.0 (SD, 11.5) years. The percentage of nurses stating a preference (strong or slight) for the Somatuline Autogel syringe (86.2% [95% CI 77.5-92.4%]) was significantly higher than 50% (p < 0.0001). Performance rating was significantly higher for the Somatuline Autogel syringe versus Lanreotide Pharmathen syringe for 10 of the 11 attributes tested (p < 0.05). The syringe attributes considered most important when injecting patients in routine clinical practice were easy to use from preparation to injection (30.9%) and comfortable to handle during use from preparation to injection (16.0%). The attribute most commonly rated as least important was fast administration from preparation to injection (26.6%).Nurses strongly preferred the user experience of the Somatuline Autogel syringe over the Lanreotide Pharmathen syringe. Ease of use and comfortable to handle were the most important syringe attributes, and performance rating was significantly higher with Somatuline Autogel versus Lanreotide Pharmathen syringe for all but one attribute.Drugs called somatostatin analogues (SSAs) can be used to treat patients with neuroendocrine tumours or acromegaly over a prolonged period of time. SSAs are given as injections and act by slowing the production of hormones by the body and in some cases reducing the growth of the tumour. To help to provide the best care possible, it is important that the syringe used for the injection is easy to use and delivers the SSA effectively. Somatuline Autogel is a syringe that can be used to inject an SSA called lanreotide. Previous studies showed that patients and nurses preferred the injection experience when using the Somatuline Autogel syringe compared with a syringe used to inject another SSA called octreotide long-acting release. A new syringe used for lanreotide injections has been developed recently by a company called Pharmathen. In the PRESTO 3 study, we compared the user experience of the Somatuline Autogel syringe and the Lanreotide Pharmathen syringe. We asked 94 nurses from Europe and the US to test both syringes, in a randomised order, using injection pads, and then to answer questions about their overall preference between the two syringes and how well the syringe performed for a set of syringe features. Overall, 86% of nurses preferred the Somatuline Autogel syringe over the Lanreotide Pharmathen syringe. Of the 11 features of the syringe that we assessed, 10 were rated higher for the Somatuline Autogel syringe than the Lanreotide Pharmathen syringe. The syringe features “ease of use” and “comfortable to handle” were considered the most important. The results of the PRESTO 3 study indicated that there is a difference in the user experience between the syringes, particularly for confidence and ease of use, and that it is important to offer syringe choices to nurses who are using SSA injections to treat patients." @default.
• W4385661567 created "2023-08-09" @default.
• W4385661567 creator A5006986996 @default.
• W4385661567 creator A5015601354 @default.
• W4385661567 creator A5015622998 @default.
• W4385661567 creator A5023129196 @default.
• W4385661567 creator A5046852415 @default.
• W4385661567 creator A5048037056 @default.
• W4385661567 creator A5061061870 @default.
• W4385661567 date "2023-08-08" @default.
• W4385661567 modified "2023-10-10" @default.
• W4385661567 title "An international simulated-use study to assess nurses’ preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3)" @default.
• W4385661567 cites W1965366920 @default.
• W4385661567 cites W2110355300 @default.
• W4385661567 cites W2155465275 @default.
• W4385661567 cites W2163021856 @default.
• W4385661567 cites W2229261843 @default.
• W4385661567 cites W2934475215 @default.
• W4385661567 cites W2980973318 @default.
• W4385661567 cites W2981628757 @default.
• W4385661567 cites W3010956579 @default.
• W4385661567 cites W3120999585 @default.
• W4385661567 cites W4311052876 @default.
• W4385661567 doi "https://doi.org/10.1007/s40618-023-02158-5" @default.
• W4385661567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37550552" @default.
• W4385661567 hasPublicationYear "2023" @default.
• W4385661567 type Work @default.
• W4385661567 citedByCount "0" @default.
• W4385661567 crossrefType "journal-article" @default.
• W4385661567 hasAuthorship W4385661567A5006986996 @default.
• W4385661567 hasAuthorship W4385661567A5015601354 @default.
• W4385661567 hasAuthorship W4385661567A5015622998 @default.
• W4385661567 hasAuthorship W4385661567A5023129196 @default.
• W4385661567 hasAuthorship W4385661567A5046852415 @default.
• W4385661567 hasAuthorship W4385661567A5048037056 @default.
• W4385661567 hasAuthorship W4385661567A5061061870 @default.
• W4385661567 hasBestOaLocation W43856615671 @default.
• W4385661567 hasConcept C118552586 @default.
• W4385661567 hasConcept C126322002 @default.
• W4385661567 hasConcept C2777433750 @default.
• W4385661567 hasConcept C2778571141 @default.
• W4385661567 hasConcept C2779609023 @default.
• W4385661567 hasConcept C2984496839 @default.
• W4385661567 hasConcept C71315377 @default.
• W4385661567 hasConcept C71924100 @default.
• W4385661567 hasConceptScore W4385661567C118552586 @default.
• W4385661567 hasConceptScore W4385661567C126322002 @default.
• W4385661567 hasConceptScore W4385661567C2777433750 @default.
• W4385661567 hasConceptScore W4385661567C2778571141 @default.
• W4385661567 hasConceptScore W4385661567C2779609023 @default.
• W4385661567 hasConceptScore W4385661567C2984496839 @default.
• W4385661567 hasConceptScore W4385661567C71315377 @default.
• W4385661567 hasConceptScore W4385661567C71924100 @default.
• W4385661567 hasFunder F4320314481 @default.
• W4385661567 hasLocation W43856615671 @default.
• W4385661567 hasLocation W43856615672 @default.
• W4385661567 hasOpenAccess W4385661567 @default.
• W4385661567 hasPrimaryLocation W43856615671 @default.
• W4385661567 hasRelatedWork W1969193394 @default.
• W4385661567 hasRelatedWork W1985028592 @default.
• W4385661567 hasRelatedWork W2033892624 @default.
• W4385661567 hasRelatedWork W2056384838 @default.
• W4385661567 hasRelatedWork W2159395850 @default.
• W4385661567 hasRelatedWork W2163115926 @default.
• W4385661567 hasRelatedWork W2291829517 @default.
• W4385661567 hasRelatedWork W2524546317 @default.
• W4385661567 hasRelatedWork W3176700037 @default.
• W4385661567 hasRelatedWork W73203029 @default.
• W4385661567 isParatext "false" @default.
• W4385661567 isRetracted "false" @default.
• W4385661567 workType "article" @default.